Navigation Links
SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
Date:9/12/2007

ISELIN, N.J., Sept. 12 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD.OB), today announced that it will host a symposium entitled "Post-Operative Adhesions in Cardiac Surgery: Challenges and Solutions" for surgeons attending next week's European Association for Cardio- Thoracic Surgery Annual Meeting in Geneva, Switzerland. The symposium will be chaired by Professor Stephen Westaby of the John Radcliffe Hospital in Oxford, United Kingdom and will include presentations by principal investigators who participated in US and European clinical trials for REPEL-CV(R) Adhesion Barrier, the company's novel bioresorbable film intended to reduce the formation of adhesions (scar tissue) in cardiac surgical procedures. Professor Westaby stated, "It is important to inform our surgeon colleagues that, with REPEL-CV, we now appear to a have way of reducing patient risks associated with the presence of adhesions during cardiac reoperations."

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion and drug delivery products based on its proprietary bioresorbable polymer technology.

Statements in this Press Release that are not statements of historical fact, including statements regarding indications of the timing or ability to achieve regulatory approval and market launch for REPEL-CV or the potential market size for REPEL-CV, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the Company's effor
'/>"/>

SOURCE SyntheMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Symposium will include venture capital "coaching"
2. Fusion 2006 symposium focuses on making IT work for businesses
3. Early Stage Symposium session will help emerging companies prepare for investors
4. Food microbiology symposium will mark 25 years
5. High interest forces delay in food safety symposium
6. Milwaukee to host inaugural Great Lakes Agro-Security Symposium
7. Fusion 2005 symposium aims to bring CIOs to the boardroom
8. Wisconsin Technology Network presents symposium on saving lives by the use of Information Technology
9. UW symposium to explore impact of IT on improving quality, safety and cost of healthcare
10. Symposium examines the effect of race on genetics and disease
11. Belmont Report Commission reuniting for Medical College of Wisconsin Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Researchers often use microelectronic ... but such devices can do much more – ... such, researchers have looked to patterned assemblies of ... metabolic engineering to characterize – and potentially control ... are envisioned to recreate animal and human physiological ...
(Date:7/30/2014)... July 30, 2014 Connecticut Center for ... based in East Hartford, Conn., was awarded a Rural ... of a project that will determine the feasibility of ... north-central Connecticut. USDA Rural Development provided $53,000 for CCAT ... the second phase of the feasibility study in fiscal ...
(Date:7/29/2014)... (PRWEB) July 30, 2014 ... and collaboration company, is proud to announce the ... management positions in their Boston, Charleston and Atlanta ... to the increased demand for hosted solutions, collaboration ... efficiency and reduce cost. , SoundConnect was founded ...
(Date:7/29/2014)... , July 29, 2014 Human Longevity, Inc. ... company focused on extending the healthy, high performance human ... Och , Ph.D., an expert in machine learning and ... comes to HLI from Google where he was Distinguished ... will report directly to HLI Co-Founder and CEO, ...
Breaking Biology Technology:UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3SoundConnect Organization and Culture is Evolving 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3
... 10 Varian, Inc.,(NasdaqGS: VARI) announced the release ... applications involving liquid-state samples. The,OneNMR Probe product line ... a single probe rather than switching probes for,different ... and,research chemists performing a broad range of common ...
... TOKYO, and REDWOOD CITY, Calif., March 10, Otsuka ... PDLI ) today announced the closing of ... PDL,s,rights to IV Busulfex(R) (busulfan), including trademarks, patents,intellectual ... inventory,value., IV Busulfex is an oncologic product ...
... (Amex: PTN ) announced today the completion ... novel, long-acting natriuretic peptide,receptor A (NPRA) agonist under ... (CHF). The Phase I trial was a,randomized, double-blind, ... volunteers who received the medication or placebo,subcutaneously. The ...
Cached Biology Technology:Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses 2Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 2Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 3Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 4Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 2Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 3Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 4
(Date:7/30/2014)... team of biologists, led by Clemson University associate professor ... pest that will pave the way for novel anti-fouling ... for medical and industrial applications. , The team,s findings, ... the last larval stage of barnacles that attaches to ... possibly polymeric material that acts as an underwater heavy-duty ...
(Date:7/30/2014)... today announced an across-the-board increase in Impact Factors ... InCites Journal Citation Reports (Thomson Reuters, 2014) show ... , Essays in Biochemistry , Biochemical ... all received increases in their Impact Factors. The ... published by Portland Press Limited. , 2014 Impact ...
(Date:7/30/2014)... professor from Wayne State University,s College of Engineering ... Science Foundation for the project, "Nanoparticle-directed synthesis of ... Science Foundation, nanotechnology is the creation and utilization ... properties and functions. A major bottleneck in scaling ... that connect different functional materials into one device. ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... mean lighting more bush fires, ecologists have proposed. ... threatened by encroaching woodland that is destroying their habitat, ... and Stanford University (USA) has shown. "Broad-headed snakes ... km of Sydney, and those small communities are fast ...
... Over the past few years, honey bee keepers have experienced ... honey bee populations, causing some growers of fruits, nuts and ... the future. A new study published in the Annals ... bees, which are not affected by CCD, may serve as ...
... team of scientists from the National Institute of Oceanography ... expedition on research vessel Polarstern. The cooperative project Lohafex ... But it has dampened hopes on the potential of ... dioxide (CO 2 ) and thus mitigate global warming. ...
Cached Biology News:Australia's most endangered snake might need burning 2Wild bees can be effective pollinators 2Lohafex provides new insights on plankton ecology 2Lohafex provides new insights on plankton ecology 3Lohafex provides new insights on plankton ecology 4
APO-BrdU™ TUNEL Assay Kit *with Alexa Fluor® 488 anti-BrdU* *60 assays*...
The FlowTACS Apoptosis Detection Kit is designed specifically for in situdetection of apoptotic...
Recombinant Rat PTX2/SAP...
Request Info...
Biology Products: